Will Boehringer give Yuhan Corporation ‘Jardiance’?

As ‘Jardiance(generic name: empagliflozin),’ a SGLT-2 inhibitor, is anticipated to receive the insurance benefit in the 1^st half of the year at the latest, the industry has paid attention on which company will become the partnering company for the co-promotion.

Although Yuhan Corporation was a strong candidate as establishing the co-promotion MOU with Boehringer Ingelheim last September, a rum...